Abstract: Disclosed are methods useful for the topical therapeutic treatment of skin malignancies including skin cancers and cutaneous metastases using compositions containing nanoparticles of paclitaxel or other taxanes.

Abstract: Disclosed are oral care compositions, for example dentifrice compositions, comprising an oral care composition comprising an orally acceptable vehicle, metal oxide particles having an average particle size of no greater than a dentin tubule and at least one amino acid capable of chelating the metal oxide. The composition may comprise a polymeric adherent material for adhering the metal oxide particles in the dentin tubule. The metal oxide particles have a median particle size of 5 microns or less, and may comprise zinc oxide.

Abstract: An improved method of treating a skin barrier condition is disclosed. The method involves identifying a target portion of skin on a person where treatment is desired and applying a low-pH composition to the target portion of skin. The low-pH composition contains an effective amount of a vitamin B3 compound and has a pH of less than 5.0.

Abstract: The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.

Abstract: The Moringa oleifera nanoparticles may be synthesized by harvesting Moringa leaves, drying the Moringa leaves, powdering the dried Moringa leaves, suspending the powdered Moringa leaves in a solution, and spraying the solution into boiling water under ultrasonic conditions to obtain Moringa nanoparticles. The Moringa nanoparticles may be encapsulated by dissolving the Moringa nanoparticles and gum olibanum in ethanol to produce a mixture, injecting the inert organic phase of the mixture into an aqueous solution containing PVA, and homogenizing the aqueous solution. The Moringa nanoparticles may be useful in preventing the growth of cancer cells and in treating diabetes by inhibiting ?-glucosidase and/or ?-amylase activity.

Abstract: The present application relates to compositions comprising 4-chloroindole-3-acetic acid (4Cl-IAA) or an analogue thereof, or a combination of the latter, in the form of a potassium salt, a sodium salt or an amine salt. For example, such compositions can be used used in methods for selectively causing damage or mortality to weed.

Abstract: A composition and method for rapidly inducing a state of endogenous ketosis, the composition including: about 26.66-28.57 percent by mass of alpha lipoic acid; about 0.01-0.02 percent by mass of chromium picolinate; about 47.61-49.99 percent by mass of L-arginine; and, about 23.33-23.81 percent by mass of calcium carbonate. The method includes restricting carbohydrate consumption to a maximum dosage of about 20 grams prior to consumption of the composition and wherein consumption of the composition is on an empty stomach. About thirty minutes after consumption of the composition the user performs moderate intensity exercise. About three hours after consuming a first dose the user tests for a presence of ketones in urine utilizing at least one sodium nitroprusside urine ketone reagent strip.

Abstract: The purpose of the present invention is to provide a dosing technique for rifampicin, the technique being capable of long-term administration by enhancing the direct transfer of rifampicin to the brain and by suppressing the hepatic first-pass effect. This pharmaceutical composition for nasal administration, which contains, as an active ingredient, rifampicins selected from the group consisting of rifampicin, derivatives thereof, and salts thereof, and is used for the prevention or treatment of dementia, is capable of long-term administration by enhancing the direct transfer of rifampicin to the brain and suppressing the hepatic first-pass effect.

Abstract: The present invention relates to oral composition and the method of preparation and use of such composition for inhibiting, reducing, and/or disrupting oral biofilm. The composition comprises a stabilizing matrix, a cationic biocide, and a peroxide source.

Abstract: This invention relates to the use of chlorite-based antimicrobials in a manner where the time of biocidal activity is extended for the microbial control in the water used for drilling, completion and remediation of wells. The invention involves mixing of a compatible extender in the form of sodium chlorate with sodium chlorite to form an antimicrobial formulation. This combination is used with an acid on the site to generate chlorine dioxide which is injected into the water used for hydraulic fracturing or remedial workover. The formulation is a much more effective bactericide for the subterranean oil and gas rich formations. The potency and longevity of biocidal activity is controlled by varying the ratios of chlorate and acid which provide different profiles of the antimicrobial activities.

Abstract: The present invention, inter alia, relates to a closed sterilized container comprising at least one carrier which is a stabilizer; and at least one biomolecule reversibly attached to the carrier, wherein said carrier partially or completely covers the attached biomolecules and wherein said at least one carrier is selected from the group consisting of (poly)peptides such as dipeptides or tripeptides, amino acids, polyalcohols, polyethyleneglycols, ionic liquids, compatible solutes, saponins and a mixture thereof. The invention also relates to methods for producing sterilized containers according to the invention and uses thereof.

Abstract: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating acute wounds, chronic wounds and/or a wound or epithelial tissue surface that contains bacterial biofilm, including unexpected synergy between bismuth-thiol (BT) compounds and certain antibiotics, to provide topical formulations including antiseptic formulations, for management and promotion of wound healing and in particular infected wounds. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating gram-negative bacterial infections.

Abstract: Evaporation of water from an aqueous dispersion of a solid peroxide such as benzoyl peroxide is retarded by the incorporation of carboxylic acid salt. The carboxylic acid salt renders the aqueous dispersion less susceptible to explosive decomposition when exposed to external triggering events such as impact, heat, friction or contamination, yet does not interfere with the ability to achieve and maintain a stable, small particle size dispersion having desirable viscosity and flow properties.

Abstract: An antibacterial and deodorizing leather includes a leather body and an antibacterial and deodorizing layer. The antibacterial and deodorizing layer includes a water-based foaming material and an antibacterial deodorant. The water-based foaming material and the antibacterial deodorant are mixed and arranged on the leather body and then bonded with the leather body by hot pressing. By uniformly mixing the antibacterial deodorant and a bactericide through the water-based foaming material to become gelatinous, the antibacterial and deodorizing layer is arranged on the leather body according to the size of the leather body. Then, the antibacterial and deodorizing layer is tightly bonded with the leather body by hot pressing, achieving the effects of saving costs, simplifying the manufacturing process, and environmental protection.

Abstract: The invention provides methods and polymer compositions for treating retinal detachment and other ocular disorders, where the methods employ polymer compositions that can form a hydrogel in the eye of a subject. The hydrogel is formed by reaction of (i) a nucleo-functional polymer that is a biocompatible polymer containing a plurality of thio-functional groups —R1-SH wherein R1 is an ester-containing linker, such as a thiolated poly(vinyl alcohol) polymer and (ii) an electro-functional polymer that is a biocompatible polymer containing at least one thiol-reactive group, such as a poly(ethylene glycol) polymer containing alpha-beta unsaturated ester groups.

Abstract: Disclosed are stable microcapsule compositions each containing a microcapsule dispersed in an aqueous phase and a stabilizing agent. The microcapsule compositions are stable for at least 4 weeks when storing at 45° C., and the microcapsule composition is considered stable when (i) the composition has a viscosity of 3000 cP or less and (ii) 20% or less water by volume of the composition is separated from the composition. Also disclosed are consumer products having such a stable microcapsule composition.

Abstract: The present invention relates to Bacillus methylotrophicus strain DR-08 which produces a natural volatile compound and has antimicrobial activity, and a use thereof. The Bacillus methylotrophicus strain DR-08 according to the present invention, which is an antagonistic microorganism for controlling phytopathogenic microorganisms, and secondary metabolites produced by the strain, which include antibacterially- and antifungally-active non-volatile and volatile materials, are harmless to humans and domestic animals, and exhibit excellent control activity against various phytopathogenic bacteria and fungi while not causing environmental pollution. Thus, the strain and the secondary metabolites can be very usefully used for controlling various plant diseases in an environmentally-friendly manner.

Abstract: An ophthalmic composition or dosage form can include a therapeutically effective amount of a copper-containing agent that is sufficient to increase corneal lysyl oxidase activity in an eye of a subject in an amount sufficient to treat myopic progression and a pharmaceutically acceptable carrier. The composition or dosage form can be used to treat or prevent progression of myopia by administering a therapeutically effective amount of the composition to an eye of a subject during a treatment period.

Abstract: Methods for improving the ability of a population of biological agents to compete and survive in a field setting are provided. By improving the population of biological agents, the modified population of agents is able to grow, compete with other microbial strains and fungi, and provide protection for plants from pathogens. In particular, modified biological agents and modified populations of such agents that are herbicide tolerant or resistant are selected or engineered. In this manner, the protection from disease-causing agents is enhanced. Such modified populations of biological agents can be added to soils to prevent fungal pathogens and the diseases they cause promoting plant growth. Therefore, the present invention is useful for enhancing the competitiveness of modified biological agents particularly over other microbial agents which are not herbicide resistant.

Abstract: Provided herein are methods treating a disease or disorder in or around the eye with a pharmaceutical composition comprising selenium disulfide (SeS2) and instructing the treated individual to limit or avoid exposure to light following administration in order to reduce the adverse effect of the composition.